Dagco Inc. Purchases Shares of 577,540 SELLAS Life Sciences Group, Inc. $SLS

Key Points

• Dagco Inc. bought a new stake of 577,540 shares in SELLAS Life Sciences (~$2.18 million), representing about 0.41% of the company at quarter-end.
• SELLAS shares opened at $4.76 (down ~8.5%), the company has a market cap of $678M and reported Q EPS of ($0.05) beating estimates by $0.01, while analysts forecast a full-year EPS of -0.57.
• Analyst views are mixed—Maxim raised its price target to $10 and rated the stock Buy, Weiss Ratings maintained a Sell, and MarketBeat shows a consensus Hold with a $10 target; institutional investors own about 17.38% of the stock.

Dagco Inc. purchased a new stake in shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 577,540 shares of the company's stock, valued at approximately $2,177,000. Dagco Inc. owned about 0.41% of SELLAS Life Sciences Group at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Bank of America Corp DE grew its holdings in SELLAS Life Sciences Group by 21.9% in the 3rd quarter. Bank of America Corp DE now owns 42,150 shares of the company's stock worth $68,000 after buying an additional 7,571 shares in the last quarter. BNP Paribas Financial Markets raised its stake in SELLAS Life Sciences Group by 89.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 19,724 shares of the company's stock valued at $32,000 after acquiring an additional 9,299 shares in the last quarter. Opus Capital Group LLC raised its stake in SELLAS Life Sciences Group by 4.2% during the 3rd quarter. Opus Capital Group LLC now owns 250,000 shares of the company's stock valued at $403,000 after acquiring an additional 10,000 shares in the last quarter. Equitable Holdings Inc. boosted its position in SELLAS Life Sciences Group by 58.6% during the 3rd quarter. Equitable Holdings Inc. now owns 27,060 shares of the company's stock worth $44,000 after acquiring an additional 10,000 shares during the period. Finally, Axxcess Wealth Management LLC acquired a new position in SELLAS Life Sciences Group during the 3rd quarter worth $26,000. 17.38% of the stock is currently owned by institutional investors and hedge funds.

SELLAS Life Sciences Group Stock Down 8.5%

Shares of SELLAS Life Sciences Group stock opened at $4.76 on Monday. The business has a fifty day simple moving average of $4.45 and a 200-day simple moving average of $2.90. SELLAS Life Sciences Group, Inc. has a fifty-two week low of $0.95 and a fifty-two week high of $6.14. The firm has a market cap of $678.01 million, a price-to-earnings ratio of -19.04 and a beta of 2.18.

SELLAS Life Sciences Group (NASDAQ:SLS - Get Free Report) last released its earnings results on Thursday, March 19th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.06) by $0.01. Analysts anticipate that SELLAS Life Sciences Group, Inc. will post -0.57 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the company. Weiss Ratings reissued a "sell (d-)" rating on shares of SELLAS Life Sciences Group in a report on Thursday, January 22nd. Maxim Group upped their price objective on shares of SELLAS Life Sciences Group from $7.00 to $10.00 and gave the stock a "buy" rating in a report on Thursday, March 12th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat, SELLAS Life Sciences Group presently has a consensus rating of "Hold" and a consensus target price of $10.00.

SELLAS Life Sciences Group Profile

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms' tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient's own immune system to recognize and attack WT1-positive cancer cells.

The company's lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.

Want to see what other hedge funds are holding SLS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.